Hyphens Pharma International Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

See Wah Lim

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	6.9yrs
CEO ownership	n/a
Management average tenure	1.4yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

CEO

See Wah Lim (56 yo)

6.9yrs

Tenure

Mr. Lim See Wah serves as Executive Chairman, Director and CEO of Hyphens Pharma International Limited. He was appointed to the Board of Hyphens Pharma International Limited on 12 December 2017. Mr. Lim Se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
See Wah Lim	Executive Chairman & CEO	no data	no data	no data
Yufan Zhang	Chief Financial Officer	1.4yrs	no data	no data
Yann Alain Marche	Chief Operating Officer	5.2yrs	no data	0.19% SGD 169.2k
Tay Keow	Head of HR & Admin	less than a year	no data	no data
Yeo Jason	Managing Director of Pan-Malayan Pharmaceuticals & Novem Healthcare	less than a year	no data	no data
Stella Ang	Head of Regulatory Affairs	no data	no data	no data
Jamal Iflizar	Country Head of Indonesia	no data	no data	no data
Ang Francis	Country Head of Malaysia	no data	no data	no data
Josiephine Sac Mantoya	Country Head of Philippines	2.8yrs	no data	no data
Laurence Fremy	Country Head of Vietnam	1.3yrs	no data	no data
Sher Mei Lim	Company Secretary	no data	no data	no data

1.4yrs

Average Tenure

Experienced Management: 1J5's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
See Wah Lim	Executive Chairman & CEO	6.9yrs	no data	no data
Eng Leng Ng	Independent Non-Executive Director	6.6yrs	no data	no data
Seok Hoong Tan	Independent Non-Executive Director	5.3yrs	no data	no data
Kia King Tan	Non-Executive Director	6.9yrs	no data	28.05% SGD 25.6m
Wee Koon Heng	Lead Independent Director	6.6yrs	no data	no data
Kiat Chan	Independent Director	4yrs	no data	0.039% SGD 35.4k

6.6yrs

Average Tenure

56yo

Average Age

Experienced Board: 1J5's board of directors are considered experienced (6.6 years average tenure).

Hyphens Pharma International Management

Management criteria checks 1/4

Key information

Recent management updates

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Insufficient new directors

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Insufficient new directors

Insufficient new directors

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Recent updates

Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema

Price target increased by 7.1% to S$0.38

First quarter 2024 earnings released

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023

Final dividend of S$0.0086 announced

Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024

Consensus revenue estimates increase by 10%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Third quarter 2023 earnings released

Price target decreased by 10% to S$0.34

Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023

Second quarter 2023 earnings released

Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer

Price target decreased by 8.9% to S$0.39

Now 23% undervalued after recent price drop

Upcoming dividend of S$0.011 per share at 3.3% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021)

Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia

Price target increased to S$0.41

Insufficient new directors

Price target increased to S$0.41

Consensus EPS estimates increase by 12%

Second quarter 2022 earnings released

Insufficient new directors

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022

Price target decreased to S$0.35

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022

Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to S$0.35

Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020)

First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020)

Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019)

Revenue and earnings miss expectations

Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex

New 90-day low: S$0.32

Price target lowered to S$0.38

New 90-day low: S$0.34

Hyphens Pharma International Limited Announces Board Changes

Analysts update estimates

First half earnings released

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age